

UCSF

UC San Francisco Previously Published Works

Title

Atrial standstill in a pediatric patient with associated caveolin-3 mutation

Permalink

<https://escholarship.org/uc/item/4k27r8zw>

Journal

HeartRhythm Case Reports, 3(11)

ISSN

2214-0271

Authors

Gal, Dana B
Wojciak, Julianne
Perera, Jennifer
et al.

Publication Date

2017-11-01

DOI

10.1016/j.hrcre.2017.07.014

Peer reviewed

Atrial standstill in a pediatric patient with associated caveolin-3 mutation



Dana B. Gal, MD,* Julianne Wojciak, MS,[†] Jennifer Perera, MD,[†] Ronn E. Tanel, MD,[†] Akash R. Patel, MD[†]

From the *Department of Pediatrics, University of California, San Francisco, San Francisco, California, and [†]Department of Pediatric Cardiology, University of California, San Francisco, San Francisco, California.

Introduction

Atrial standstill (AS), a rare arrhythmogenic condition, is defined by (1) the absence of P waves in surface and intracavitary electrocardiograms (ECGs), (2) the absence of A waves in jugular venous pulse and right atrial pressure tracings, (3) the presence of a supraventricular type QRS complex, (4) the immobility of the atria on fluoroscopy, and (5) the inability to stimulate the atria electrically.¹ Several etiologies have been identified including metabolic derangements, ischemia, drug intoxication, amyloidosis, and muscular dystrophies.¹ The discovery of familial AS leads to the identification of channelopathies involved, particularly *SCN5A* mutations leading to Nav1.5 sodium channel dysfunction.¹ AS is rarely reported in pediatric patients. An 11-year-old with permanent AS was found to have an *SCN5A* mutation; a 3-year-old developed AS transiently after dexmedetomidine infusion; and systemic illness was implicated in an 8-year-old with thiamine-responsive megaloblastic anemia.^{1–3} Here we present a unique case of AS, possibly due to novel caveolin-3 (*CAV3*) mutation, in a pediatric patient whose clinical presentation and progression were unusual.

Case report

An African American male patient presented with palpitations and syncope at the age of 12 years. His ECG initially revealed accelerated junctional rhythm with intermittent isolated ventricular ectopy (Figure 1A). With metoprolol, he had improved ectopy but Holter monitoring and subsequent ECG showed continued junctional rhythm and episodes of nonsustained atrial tachycardia alternating with junctional bradycardia with 3-second pauses (Figure 1B). Further evaluation with echocardiography

showed normal biatrial size with no atrial contraction (Figure 2). Cardiac magnetic resonance imaging showed normal morphology, function, and no delayed myocardial enhancement. Subsequent exercise testing revealed no sinus node activity and no sinus P waves. The rhythm was predominantly junctional with a maximum rate of 184 and episodes of nonsustained atrial tachycardia during exercise and recovery. He also had a 3-second pause during exercise with associated dizziness. Because of these findings and history of fatigue and frequent presyncopal episodes, he was taken off metoprolol, causing improvement in his symptomatic bradycardia but worsening of symptomatic tachyarrhythmia.

An electrophysiology study showed inducible left anterior mitral valve annulus atrial tachycardia, which was successfully ablated (Figure 3A). The left atrium appeared healthy without evidence of electrical scar. The right atrium showed small to no atrial activity with no atrial capture at high outputs. Voltage mapping showed significant right atrial scar (Figure 3B). After ablation, his symptomatic atrial tachycardia resolved but he remained in junctional rhythm with worsened fatigue and exercise intolerance. A repeat ECG showed marked junctional bradycardia without evidence of atrial activity (Figure 1C). Repeat Holter monitoring showed junctional bradycardia with more frequent and longer pauses, up to 5.1 seconds, and episodes of junctional tachycardia.

He underwent a second electrophysiology study 4 months after the initial procedure during planned implantation for a dual-chamber pacemaker. This study showed progressive right atrial disease (Figure 3C) and lack of right atrial sensing or capture with transvenous atrial lead placement attempts, so a single-chamber ventricular pacemaker was placed. This clinical course and findings were consistent with AS.

Since device placement, serial ECGs over 2 years continue to show junctional rhythm and follow-up device checks show chronic ventricular pacing with increasing dependence at 69% with heart rate set at 50 beats/min suggesting disease progression (Figure 1D). His family history is reassuring, but his asymptomatic parents refuse evaluation including ECGs and genetic testing. Because of his unusual course, he underwent genetic testing with comprehensive

KEYWORDS Atrial standstill; Arrhythmia; Channelopathy; *CAV3*; Caveolin-3; Pediatrics
(Heart Rhythm Case Reports 2017;3:513–516)

Address reprint requests and correspondence: Dr Dana B. Gal, Department of Pediatrics, University of California, San Francisco, 550 16th St, 4th Floor, Box 0110, San Francisco, CA 94143. E-mail address: dana.gal@ucsf.edu.

KEY TEACHING POINTS

- Atrial standstill is a rare arrhythmogenic disorder that has previously been associated with systemic disease and specific channelopathies, particularly *SCN5A* mutations.
- Reports of atrial standstill are rare in the pediatric literature and are most commonly associated with structural heart disease.
- Caveolin-3 mutations have been previously associated with systemic diseases but have not been previously reported in association with atrial standstill.
- Caveolin-3 mutation is possibly responsible for atrial standstill in the patient reported here.

arrhythmia panel through GeneDx (Gaithersburg, MD), which analyzed 30 genes known to cause arrhythmia syndromes. Of those 30 genes, 2 have been associated with AS—*RYR2* and *SCN5A*. Our patient's testing was negative for *RYR2* and *SCN5A* but did reveal mutation in *CAV3*. His mutation p.Leu84Pro (L84P) is a semiconservative amino acid substitution. It was initially classified as a likely pathogenic mutation, but given that there are no published reports on this variant, no functional studies, and no segregation data, it was reclassified as a variant of unknown significance. This mutation has not been reported as a benign polymorphism and was not observed in 6500 individuals in the NHLBI GO Exome Sequencing Project.

Discussion

AS with associated tachyarrhythmia and a progressive course is an unusual presentation. Many reports of AS in the literature are in patients with structurally abnormal hearts. In the adult literature, there are reports of structural abnormality related to cardiomyopathies secondary to systemic illnesses as well as related to muscular dystrophies.¹ In the pediatric literature, reports typically describe children with congenital heart disease including atrial septal defects, tetralogy of Fallot, and Ebstein anomaly.^{1–3} In contrast, our patient had no structural abnormalities. To date, only one other pediatric case of AS without structural abnormalities has been reported in a patient with *SCN5A* mutation.¹

Prior cases of AS have been reported in the adult literature with tachyarrhythmias in Brugada syndrome due to *SCN5A* mutation and catecholaminergic polymorphic ventricular tachycardia associated with *RYR2* mutation.^{4,5} Jorat et al⁶ reported a case of isolated right AS with left atrial tachycardia in a 32-year-old female patient. Like our patient, she presented with chronic fatigue and dyspnea suggestive of bradycardia and a progressive course. She was diagnosed with AS, but no genetic testing was performed. This case,




Figure 1 Progressive electrocardiograms (ECGs) demonstrating rhythm over time. **A:** Initial ECG showing junctional rhythm with isolated ectopic beats. **B:** ECG from presentation showing junctional rhythm with episodes of nonsustained atrial tachycardia. **C:** ECG after ablation showing junctional bradycardia and no evidence of atrial activity approximately 2 weeks after the first ECG. **D:** Last available ECG obtained 5 months after ablation with no evidence of atrial activity.

and ours, differs from those in the pediatric literature because of the associated atrial tachycardia and rapidly progressive clinical course.

Cardiac channelopathies have also been implicated as a cause of AS. *SCN5A* have been identified for some time as causing AS, among other rhythm issues.^{1,7} More recently, familial *RYR2* has been associated with AS.⁴ Bhuiyan et al⁴ described 2 unrelated family pedigrees with *RYR2* mutations.




Figure 2 Echocardiograms demonstrating (A) lack of atrial contraction, (B) absence of the a' wave, and (C) absence of the a wave.

In each family, 1 individual developed AS including a 14-year-old female patient. Functional studies have not been performed with the specific mutation found in these patients with AS.⁴ Other channelopathies have not been reported in relation to AS.

Our patient had neither *RYR2* nor *SCN5A* mutation but was found to have a novel mutation in *CAV3*. The *CAV3* gene codes for CAV3, a protein essential in the formation of caveolae needed for endocytosis and cell signal transduction on muscle cell membranes. Mutations in *CAV3* are associated with a variety of human muscular diseases. In skeletal muscles, *CAV3* deficiency can cause limb-girdle muscular dystrophy (LGMD), isolated hyperCKemia, rippling muscle disease, and distal myopathy.⁸ *CAV3* is particularly concentrated in cardiomyocytes and plays a large role in cardiac physiology.⁹ It is therefore unsurprising that mutations in *CAV3* are also associated with cardiac disease including hypertrophic cardiomyopathy, long QT syndrome, and SIDS.^{8,10–12}

Numerous associations have been identified between *CAV3* and ion channels and exchangers, particularly sodium channels and exchangers. Bossuyt et al⁹ demonstrated that *CAV3* coprecipitates with the cardiac sodium-calcium exchanger, *NCX1*. *NCX1* is involved in the regulation of myocardial contractility; therefore, this association emphasizes the role *CAV3* plays in contractility. In addition, the human cardiac voltage-gated sodium channel *hNav1.5*,

coded by *SCN5A*, has been localized to caveolae. Specifically, it has been suggested that *CAV3* and *hNav1.5* may be part of the same macromolecular protein complex.¹¹ Necessary for fast influx of sodium, the *hNav1.5* channel allows depolarization of the cell, leading to the cardiac action potential. The interaction between *hNav1.5* and *CAV3* again highlights the role *CAV3* plays in cardiac contractility and function.

While *CAV3* mutations have not previously been associated with AS, *SCN5A* mutations are among the most commonly genetically identified causes of AS.⁷ It is therefore plausible that a mutation in *CAV3* could inherently prevent normal function of *hNav1.5* if the *CAV3* protein is necessary for the normal presence of *hNav1.5* on cell membranes in caveolae. With this assumption, it may be extrapolated that a mutation in *CAV3* could lead to the same phenotypic disease of a mutation in *SCN5A* by preventing the function of its encoded protein, without having that mutation present.

Beyond the functional relationship between *CAV3* and *hNav1.5*, it is notable that the genes which encode both proteins are relatively near each other in the genome. *SCN5A* and *CAV3* are both found on the third chromosome. An event in genetic replication that mutates one of these genes could feasibly alter the other as well, as they are genetic “neighbors.” Given that *CAV3* mutations are implicated in LGMD, which is in itself associated with AS, it is possible that coinheritance of genetic polymorphisms determines




Figure 3 A: Voltage mapping from the first electrophysiology study showing focus of left atrial tachycardia near the anterior mitral annulus, which was subsequently ablated. B and C: Voltage mapping from the first (panel B) and second (panel C) electrophysiology studies demonstrating progressive right atrial scar.

whether patients with LGMD have AS.⁸ If *CAV3* mutations become a more recognized etiology of AS, the opposite could be true as well—that polymorphisms determine whether patients with AS manifest LGMD when *CAV3* is responsible. Incomplete penetrance in AS due to *SCN5A* mutations has been attributed to coinherited genetic polymorphisms, so this could also be true with *CAV3* mutations and various clinical presentations of the mutation.⁷

The association between *CAV3* and hNav1.5 is well established, as is the dysfunction of hNav1.5 channels in AS, as demonstrated by the commonality of *SCN5A* mutations in patients with AS. What is novel about this case is the fact that his AS cannot be attributed to a previously associated genetic mutation and the fact that his *CAV3* mutation and AS are not accompanied by simultaneous skeletal muscle disease. It is possible that he may develop LGMD in the future and that his illness simply presented with AS rather than other symptoms, though even this would be unusual for the natural history of LGMD. Hong et al noted that “neuromuscular symptoms precede cardiological symptoms in nearly all patients with LGMD1B.”¹³ It is also possible that the degree to which our patient’s mutation affects his muscles is only clinically relevant in his heart, as suggested by Hayashi et al¹⁰ in cases of *CAV3* mutation–associated cardiomyopathy without associated skeletal muscle disease. They explain that continuous beating of the heart might make it vulnerable to even minor disturbances whereas the voluntary nature of skeletal muscle contraction could mean that it is not affected by small functional changes.

Lastly, embryological differences between the left and right atria could make the tissues differentially susceptible to genetic mutation such as *CAV3*. The distribution of connexins and orientation of fibers differs throughout the heart and affect conduction propagation.¹⁴ Christoffels and Moorman¹⁵ comment in their 2009 article that under pathological conditions such as gene defects, the embryonic origin of certain tissues within the myocardium could play a role in the clinical manifestation of conductive issues. In addition, they highlight the importance of differentiation of the embryonic heart tube via specific regulatory pathways that give rise to the formation and function of the conduction system and associated “conducting” cardiac myocytes based on anatomic location.¹⁵ This suggests that there could be differential effects of *CAV3* mutations in different parts of the heart based on their embryonic origin.

While there does seem to be evidence in the literature that a *CAV3* mutation could lead to AS, it is important to note that this mutation remains classified as a variant of unknown significance and is not definitively disease causing. We are limited in our ability to fully understand this case because of the lack of functional testing as well as the refusal of

genetic testing by his family members. With time, it is possible that *CAV3* mutations could be associated with other cases of AS, lending support to the hypotheses we have presented here, but at present we are certainly limited in our full understanding of the implications of this patient’s *CAV3* mutation and its relationship with his disease.

Conclusion

We have presented a unique, unusual case of pediatric AS with associated focal ectopic atrial tachycardia and progressive clinical course in a patient who has a novel mutation in *CAV3*.

References

1. Baskar S, Ackerman M, Clements D, Mayuga K, Aziz P. Compound heterozygous mutations in the *SCN5A*-encoded Nav1.5 cardiac sodium channel resulting in atrial standstill and His-Purkinje system disease. *J Pediatr* 2014; 165:1050–1052.
2. Shepard S, Tejman-Yarden S, Khanna S, Davis CK, Batra AS. Dexmedetomidine-related atrial standstill and loss of capture in a pediatric patient after congenital heart surgery. *Crit Care Med* 2011;39:187–189.
3. Doğan V, Senocak F, Orün UA, Ceylan O. Heart failure after transvenous closure of atrial septal defect associated with atrial standstill and thiamine-responsive megaloblastic anemia. *Turk Kardiyol Dem Ars* 2013;41:638–641.
4. Bhuiyan ZA, van den Berg MP, van Tintelen P, Bink-Boelkens MTE, Wiesfeld ACP, Alders M, Postma AV, van Langen I, Mannens M, Wilde AAM. Expanding spectrum of human RYR2-related disease. *Circulation* 2007;116:1569–1576.
5. Takehara N, Makita N, Kawabe J, Sato N, Kawamura Y, Kitabatake A, Kikuchi K. A cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill. *J Intern Med* 2004;255:137–142.
6. Jorat MV, Nikoo MH, Yousefi A. Persistent isolated right atrial standstill associated with left atrial tachycardia. *Res Cardiovasc Med* 2014;3:e25173.
7. Makita N, Sasaki K, Groenewegen WA, Yokota T, Yokoshiki H, Murakami T, Tsutsui H. Congenital atrial standstill associated with coinheritance of a novel *SCN5A* mutation and connexin 40 polymorphisms. *Heart Rhythm* 2005; 2:1128–1134.
8. Gazzo E, Sotgia F, Bruno C, Lisanti M, Minetti C. Caveolinopathies: from the biology of caveolin-3 to human diseases. *Eur J Hum Genet* 2010;18:137–145.
9. Bossuyt J, Taylor BE, James-Kracke M, Hale CC. Evidence for cardiac sodium-calcium exchanger association with caveolin-3. *FEBS Lett* 2002;511:113–117.
10. Hayashi T, Arimura T, Ueda K, Shibata H, Hohda S, Takahashi M, Hori H, Koga Y, Oka N, Imaizumi T, Yasunami M, Kiumura A. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. *Biochem Biophys Res Commun* 2004;313:178–184.
11. Vatta M, Ackerman M, Ye B, Mekielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, Kamp TJ, Towbin JA. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. *Circulation* 2006;114:2104–2112.
12. Aravamudan B, Volonte D, Ramani R, Gursoy E, Lisanti MP, London B, Galbiati F. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. *Hum Mol Genet* 2013;12:2777–2788.
13. Hong J, Ki C, Kim J, Suh Y, Kim JS, Baek KK, Kim BJ, Ahn KJ, Kim D. Cardiac dysrhythmias, cardiomyopathy and muscular dystrophy in patients with Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy type 1B. *J Korean Med Sci* 2005;20:283–290.
14. Mirzoyev S, McLeod C, Asirvatham S. Embryology of the conduction system for the electrophysiologist. *Indian Pacing Electrophysiol J* 2010;10:329–338.
15. Christoffels V, Moorman A. Development of the cardiac conduction system: why are some regions of the heart more arrhythmogenic than others? *Circ Arrhythm Electrophysiol* 2009;2:195–207.